[Myasthenia gravis].
Tanaka
Keiko
K
Department of Neurology, Brain Research Institute, Niigata University.
D001323:Autoantibodies / Q000302:isolation & purification; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage; D007163:Immunosorbent Techniques; D007164:Immunosorbents; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009157:Myasthenia Gravis / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D010951:Plasma Exchange / Q000379:methods; D010956:Plasmapheresis / Q000379:methods; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D011978:Receptors, Nicotinic / Q000276:immunology; D013934:Thymectomy
D001323:Autoantibodies; D016756:Immunoglobulins, Intravenous; D007164:Immunosorbents; D007166:Immunosuppressive Agents; D011978:Receptors, Nicotinic; D011239:Prednisolone